Predictive biomarkers should already stand among the most powerful forces in modern drug development. They refine treatment selection, reduce exposure to therapies unlikely to work, and help avert the risk of late‑stage setbacks before they materialise. Few levers offer this degree of strategic leverage, yet few remain so underexploited.
The gap between potential and practice is striking. Despite years of progress, predictive biomarkers still sit at the margins in many therapeutic areas. Outside oncology and certain rare diseases, I still see them treated as optional additions rather than core design principles – a mindset that now carries a rising cost.
Pressure throughout the ecosystem is intensifying. Clinical expectations, regulatory thinking, and payer scrutiny are converging around targeted approaches that demand clear justification of who benefits and why. Predictive insight should be guiding programme design, patient segmentation, evidence generation, and commercial strategy from the outset. Instead, it often arrives too far in the process or is applied inconsistently. Trials recruit broader cohorts than necessary, and value propositions rely on assumptions that biomarker work could have resolved far sooner.
If the rationale is this compelling, the question becomes unavoidable: why hasn’t predictive biomarker use become standard practice?
The case for action
Industry-wide, approval rates remain low; however, biomarker‑guided development routinely outperforms non‑stratified approaches. In programmes I’ve supported or reviewed, studies grounded in predictive hypotheses typically run with smaller, more focused cohorts, progress more efficiently, and show higher technical success. Diagnostic turnaround improves when pathways are designed with biomarkers in mind, and patient‑treatment alignment strengthens when predictive insights inform selection.
Regulators have already acknowledged this direction of travel. The FDA continues to expand qualification pathways and expectations for companion diagnostics, while the EMA increasingly integrates biomarker considerations into its scientific advice. Programmes anchored in targeted insight tend to produce more dependable outcomes, yet uptake still lags, hampered by entrenched scientific and operational obstacles.
Where momentum breaks: scientific ambiguity and strategic lateness
The scientific challenge is real. Several biomarkers don’t behave as binary switches. Genetic and molecular alterations often influence response along gradients, making threshold setting difficult. Testing variability compounds the issue: assay formats differ, interpretation standards diverge, and analytical methods aren’t always comparable across studies or regions. This inconsistency erodes confidence and restricts wider use.
The second barrier, and the one most within reach to fix, is timing. In many organisations, biomarker exploration begins only after early clinical signals appear. Teams attempt to retrofit predictive narratives rather than architect programmes around them. As a result, biomarkers have limited bearing on TPPs, eligibility criteria, trial architecture, regulatory planning, or downstream commercial considerations. Programmes advance with an incomplete view of which patients stand to gain the most.
The predictive readiness framework
What differentiates programmes that operationalise predictive insight from those that stall at aspiration is execution spanning four integrated capabilities.
- Precision of Evidence
Reinforcing the scientific backbone behind predictive biomarkers.
This involves generating granular datasets, characterising response gradients as opposed to relying on rigid thresholds, and applying analytical rigour capable of withstanding regulatory scrutiny and real‑world variability. By 2030, regulators and payers are likely to expect quantification of these gradients, thereby establishing continuous biomarker insight as a baseline requirement.
- Early‑Stage Design Commitment
Making predictive hypotheses a starting principle, not an afterthought.
Programmes should be engineered around stratification from inception, shaping programme direction, inclusion parameters, study structure, and evidence strategy before early data patterns harden. In my experience, when this commitment is made up front, it fundamentally changes development conversations. Looking ahead, biomarker‑led structuring will play a more central role in informing initial assumptions, adaptive design elements, and platform trial models.
- Testing Alignment
Creating reliable, reproducible diagnostic pathways that can operate globally.
Assays must be aligned, interpretation criteria harmonised, and clinical and diagnostic partners connected so predictive signals can be applied consistently across regions and treatment settings. Over the coming decade, diagnostic standardisation will become closely linked to regulatory and reimbursement expectations, making scalable testing solutions essential to the viability of new therapies.
- Market Translation
Ensuring predictive insight elevates impact beyond clinical design.
Payers and health systems will progressively seek greater precision in patient selection. Predictive biomarkers must therefore be embedded into pricing, access, and adoption plans rather than added as late adjustments. As systems shift towards precision-oriented contracting and population-specific access models, biomarkers will sit at the centre of value demonstration.
Positioning for the next decade
Predictive biomarkers are no longer scientific refinements but capabilities reshaping how programmes are designed, how evidence is generated, and how value is proven. The organisations that excel will regard predictive clarity as a distinguishing strength, not a discretionary add‑on.
Regulators are moving towards precision-by-default. Payers are demanding sharper targeting evidence. Health systems under budget pressure will favour interventions with predefined benefit populations. By 2030, programmes lacking predictive specificity will face heavier evidence burdens, slower evaluations, and tighter reimbursement constraints.
Organisations that invest now will run more streamlined programmes and yield more robust evidence, positioning themselves in line with future market norms. Those who delay will inherit greater uncertainty, higher cost exposure, and an environment that increasingly rewards teams that can clearly and credibly demonstrate who their treatments serve and why.
Predictive clarity is set to become a major dividing line across the sector. The companies that act decisively will help determine the standards that others will soon be compelled to meet.
Contact us
